NCT04155411 2022-07-27
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Shenzhen Second People's Hospital
Phase 4 Unknown
Clinical Trials
7 trialsNCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02268370 2019-11-29
TRAD
University Health Network, Toronto
Phase 2 Unknown
NCT03216070 2017-07-13
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4 Unknown
NCT01802450 2015-09-17
DASAPOST
PETHEMA Foundation
Phase 2 Unknown
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00979160 2009-09-18
Evaluation of Response of Dasatinib to Treat Mastocytosis
Federico II University
Phase 2 Unknown